Docetaxel-albumin conjugates: Preparation, in vitro evaluation and biodistribution studies

Journal of Pharmaceutical Sciences

Volumn 98, Issue 8, 2009, Pages 2718-2730

  Esmaeili, Farnaz ^a   Dinarvand, Rassoul ^a   Ghahremani, Mohammad Hossein ^a   Amini, Mohsen ^b   Rouhani, Hasti ^b   Sepehri, Nima ^a   Ostad, Seyed Nasser ^a   Atyabi, Fatemeh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Albumin; Biodistribution; Cell culture; Docetaxel; Drug conjugate; Nanoparticle; Nanotechnology

Indexed keywords

DOCETAXEL; HUMAN SERUM ALBUMIN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; TISSUE DISTRIBUTION;

EID: 68249129865     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21599     Document Type: Article

References (31)

1. Denis JN, Correa A, Greene AE. 1990. An improved synthesis of the Taxol side chain and of RP56976. J Org Chem 55:1957-1959.
2. Gelderblom H, Verweij J, Nooter K, Sparreboom A. 2001. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590-1598. (Pubitemid 32778603)
3. Esmaeili F, Atyabi F, Dinarvand R. 2007. Preparation of PLGA nanoparticles using TPGS in the spontaneous emulsification solvent diffusion method. J Exp Nanosci 2: 183-192. (Pubitemid 47342890)
4. Esmaeili F, Rad-Malekshahi M, Hosseini-Nasr M, Samadi N, Atyabi F, Dinarvand R. 2007. Preparation and antibacterial activity evaluation of rifampicin- loaded poly lactide-co-glycolide nanoparticles. Nanomed Nanotech Biol Med 3:161-167. (Pubitemid 46908907)
5. Kommareddy S, Amiji M. 2007. Biodistribution and pharmacokinetic analysis of long-circulating thiolated gelatin nanoparticles following systemic administration in breast cancer-bearing mice. J Pharm Sci 96:397-407. (Pubitemid 46363569)
6. Immordino ML, Brusa P, Arpicco S, Stella B, Dosio F, Cattel L. 2003. Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing docetaxel. J Control Release 91:417-429. (Pubitemid 36980659)
7. Bilensoy E, Gurkaynak O, Ertan M, Sen M, Hincal AA. 2008. Development of nonsurfactant cyclodextrin nanoparticles loaded with anticancer drug paclitaxel. J Pharm Sci 97:1519-1529.
8. Dosio F, Brusa P, Crosasso P, Arpicco S, Cattel L. 1997. Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J Control Release 47:293-304. (Pubitemid 27220212)
9. Duncan R. 1992. Drug-polymer conjugates: Potential for improved chemotherapy. Anticancer Drugs 3:175-210.
10. Maeda H, Seymour LW, Miyamoto Y. 1992. Conjugates of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjug Chem 3:245-258.
11. Ohkwada K, Hatano T, Yamada K, Joh K, Tsukada Y, Matsuda M. 1993. Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in rat hepatoma. Cancer Res 53:4238-4242. (Pubitemid 24146772)
12. Sharma RI, Pereira M, Schwarzbauer JE, Moghe PV. 2006. Albumin-derived nanocarriers: Substrates for enhanced cell adhesive ligand display and cell motility. Biomaterials 27:3589-3598.
13. Dosio F, Arpicco S, Brusa P, Stella B, Cattel L. 2001. Poly(ethylene glycol)-human serum albumin-paclitaxel conjugates: Preparation, characterization and pharmacokinetics. J Control Release 76:107-117. (Pubitemid 32786889)
14. Cavallaro G, Licciardi M, Caliceti P, Salmaso S, Giammona G. 2004. Synthesis, physico-chemical and biological characterization of a paclitaxel macromolecular prodrug. Eur J Pharm Biopharm 58:151-159. (Pubitemid 38781016)
15. Arechabala B, Coiffard C, Rivalland P, Coiffard LJM, de Roeck-Holtzhauer Y. 1999. Comparison of cytotoxicity of various surfactants tested on normal human fibroblast cultures using the neutral red test, MTT assay and LDH release. J Appl Toxicol 19:163-165. (Pubitemid 29225005)
16. Esmaeili F, Ghahremani MH, Esmaeili B, Khoshayand MR, Atyabi F, Dinarvand R. 2008. PLGA nanoparticles of different surface properties: Preparation and evaluation of their body distribution. Int J Pharm 349:249-255. (Pubitemid 350299701)
17. Kumar D, Tomar RS, Deolia SK, Mitra M, Mukher R, Burman AC. 2007. Isolation and characterization of degradation in docetaxel drug substance and its formulation. J Pharm Biomed Anal 43:1228-1235. (Pubitemid 46316818)
18. Win KY, Feng SS. 2005. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 26:2713-2722.
19. Holland SJ, Tighe BJ. 1992. Biodegradable polymers. In: Garderton D, Jones T, editors. Advances in pharmaceutical science, Vol.6. London: Academic Press. pp. 101-164.
20. John TA, Vogel SM, Tiruppathi C, Malik AB, Minshall RD. 2003. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 284:L187-L196. (Pubitemid 35471272)
21. Desai N, Trieu V, Yao R, et al. 2003. Evidence of greater antitumor activity of cermophor-free nanoparticle albumin-bound (nab) paclitaxel (abraxane) compared to taxol: Role of a novel albumin transporter mechanism. Breast Cancer Res Treat 92:348.
22. Panyam J, Labhasetwar V. 2004. Sustained cytoplasmic delivery of drugs with intracellular receptors using biodegradable nanoparticles. Mol Pharm 1:77-84.
23. Zhao J, Kim JE, Reed E, Li QQ. 2005. Molecular mechanism of antitumor activity of taxanes in lung cancer. Int J Oncol 27:247-256.
24. Bart J, Groen HJ, Hendrikse NH, Van Der Graf WT, Vaalburg W, Vries EG. 2000. The blood-brain barrier and oncology: New insights into function and modulation. Cancer Treat Rev 26:449-462. (Pubitemid 32094862)
25. Hennenfent KL, Govindan R. 2006. Novel formulations of taxanes: A review. Old wine in a new bottle. Ann Oncol 17:735-749.
26. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J. 2005. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oilbased paclitaxel in women with breast cancer. J Clin Oncol 23:7794-7803. (Pubitemid 46657376)
27. Yoon EJ, Chang HW, Lee MG, Lee H, Park MK, Kim CK. 1991. Pharmacokinetics of methotrexate after iv infusion of methotrexate-rabbit serum albumin conjugate to rabbits. Int J Pharm 67:177-182.
28. Fiume L, Busi C, Mattioli A, Spinosa G. 1988. Targeting of antiviral drugs bound to protein carriers. CRC Crit Rev Therap Drug Carrier Syst 4:265-284. (Pubitemid 18120090)
29. Zhang L, Hu Y, Jiang X, Yang C, Lu W, Yang YH. 2004. Camptothecin derivative-loaded poly (caprolactone- co-lactide)-b-PEG-b-poly (caprolactone-colactide) nanoparticles and their biodistribution in mice. J Control Release 96:135-148. (Pubitemid 38438496)
30. Storm G, Belliot SO, Daemen T, Lasic D. 1995. Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 17:31-48.
31. Vasey PA. 2003. Role of docetaxel in the treatment of newly diagnosed advanced ovarian cancer. J Clin Oncol 21:136s-144s.